<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409161</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0981</org_study_id>
    <secondary_id>NCI-2011-02767</secondary_id>
    <secondary_id>2010-0981</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01409161</nct_id>
  </id_info>
  <brief_title>Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia</brief_title>
  <official_title>Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well tretinoin and arsenic trioxide with or without
      gemtuzumab ozogamicin works in treating patients with previously untreated acute
      promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide,
      work in different ways to stop the growth of cancer cells, either by killing the cells, by
      stopping them from dividing, or by stopping them from spreading. Immunotoxins, such as
      gemtuzumab ozogamicin, may find certain cancer cells and kill them without harming normal
      cells. Giving tretinoin and arsenic trioxide together with gemtuzumab ozogamicin may kill
      more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic
      trioxide (ATO) can produce long-term event-free survival in patients with low-risk untreated
      acute promyelocytic leukemia (APL).

      II. Assess whether administration of gemtuzumab ozogamicin (GO) at the diagnosis in patients
      with high-risk APL (white blood cell [WBC] &gt; 10,000) and if the WBC rises to &gt; 10,000 after
      start of treatment (in patients with low-risk disease) will improve complete response (CR)
      rate without increasing toxicity in high-risk untreated APL.

      OUTLINE:

      INDUCTION: Patients receive tretinoin orally (PO) twice daily (BID), arsenic trioxide
      intravenously (IV) over 1-2 hours daily, and gemtuzumab ozogamicin IV over 2 hours once at
      weeks 1-4.

      CONSOLIDATION: Patients achieving CR receive arsenic trioxide IV 5 days per week during weeks
      1-4, 9-12, 17-20, and 25-28 and tretinoin PO BID for 2 weeks on and 2 weeks off. Treatment
      repeats every 8 weeks for up to 4 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 6-12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2011</start_date>
  <completion_date type="Anticipated">December 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>The time from the start of treatment to first documentation of disease relapse or death, assessed up to 2 years</time_frame>
    <description>Monitored using a Bayesian time-to-event model.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Promyelocytic Leukemia With PML-RARA</condition>
  <arm_group>
    <arm_group_label>Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive tretinoin PO BID, arsenic trioxide IV over 1-2 hours daily, and gemtuzumab ozogamicin IV over 2 hours once at weeks 1-4.
CONSOLIDATION: Patients achieving CR receive arsenic trioxide IV 5 days per week during weeks 1-4, 9-12, 17-20, and 25-28 and tretinoin PO BID for 2 weeks on and 2 weeks off. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)</arm_group_label>
    <other_name>Arsenic (III) Oxide</other_name>
    <other_name>Arsenic Sesquioxide</other_name>
    <other_name>Arsenous Acid</other_name>
    <other_name>Arsenous Acid Anhydride</other_name>
    <other_name>Arsenous Oxide</other_name>
    <other_name>Trisenox</other_name>
    <other_name>White Arsenic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)</arm_group_label>
    <other_name>Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody</other_name>
    <other_name>CDP-771</other_name>
    <other_name>CMA-676</other_name>
    <other_name>gemtuzumab</other_name>
    <other_name>hP67.6-Calicheamicin</other_name>
    <other_name>Mylotarg</other_name>
    <other_name>WAY-CMA-676</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)</arm_group_label>
    <other_name>2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-</other_name>
    <other_name>Aberel</other_name>
    <other_name>Airol</other_name>
    <other_name>Aknoten</other_name>
    <other_name>all trans-Retinoic acid</other_name>
    <other_name>All-trans Retinoic Acid</other_name>
    <other_name>All-trans Vitamin A Acid</other_name>
    <other_name>all-trans-Retinoic acid</other_name>
    <other_name>all-trans-Vitamin A acid</other_name>
    <other_name>ATRA</other_name>
    <other_name>Avita</other_name>
    <other_name>beta-Retinoic Acid</other_name>
    <other_name>Cordes Vas</other_name>
    <other_name>Dermairol</other_name>
    <other_name>Epi-Aberel</other_name>
    <other_name>Eudyna</other_name>
    <other_name>Renova</other_name>
    <other_name>Retin-A</other_name>
    <other_name>Retin-A MICRO</other_name>
    <other_name>Retin-A-Micro</other_name>
    <other_name>retinoic acid</other_name>
    <other_name>Retisol-A</other_name>
    <other_name>Ro 5488</other_name>
    <other_name>Stieva-A</other_name>
    <other_name>Stieva-A Forte</other_name>
    <other_name>Trans Retinoic Acid</other_name>
    <other_name>Trans Vitamin A Acid</other_name>
    <other_name>trans-Retinoic acid</other_name>
    <other_name>Tretinoinum</other_name>
    <other_name>Vesanoid</other_name>
    <other_name>vitamin A acid</other_name>
    <other_name>Vitamin A acid, all-trans-</other_name>
    <other_name>Vitinoin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of APL based on the presence of the PML-RAR-alpha fusion gene by
             cytogenetics, polymerase chain reaction (PCR), or POD test

          -  Ability to understand and the willingness to sign a written informed consent document
             indicating that they are aware of the investigational nature of the study

          -  Patients in whom therapy for APL was initiated on an emergent basis are eligible
             (patients may have already started treatment with ATRA, ATO, and/or one dose of
             idarubicin due to the urgency to start therapy early)

          -  Women of child-bearing potential must have a negative serum pregnancy test at
             screening; in addition to having a negative pregnancy test confirmed at screening, all
             female participants of childbearing potential must have a negative pregnancy test
             confirmed within 48 hours prior to dosing with the study drug

          -  All sexually active subjects (males and females of child-bearing potential) agree to
             use 2 effective methods of contraception for the duration of the study

        Exclusion Criteria:

          -  Fridericia corrected QT (QTcF) interval on the electrocardiogram (EKG) greater than
             480 milliseconds

          -  Patients with creatinine &gt; 2.5 times upper limit of normal unless felt to be related
             the underlying leukemia by the treating physician or hemolysis or Gilbert's disease

          -  Patients with total bilirubin &gt;= 2.0 times upper limit of normal unless felt to be
             related the underlying leukemia by the treating physician or hemolysis or Gilbert's
             disease

          -  Patients with alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &gt; 3
             times upper limit of normal unless felt to be related the underlying leukemia by the
             treating physician or hemolysis or Gilbert's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiran Naqvi</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kiran Naqvi</last_name>
    <phone>713-745-5073</phone>
    <email>knaqvi@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Naqvi</last_name>
      <phone>713-745-5073</phone>
    </contact>
    <investigator>
      <last_name>Kiran Naqvi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Katy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kiran Naqvi</last_name>
      <phone>713-745-5073</phone>
    </contact>
    <investigator>
      <last_name>Kiran Naqvi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Bay Area</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kiran Naqvi</last_name>
      <phone>713-745-5073</phone>
    </contact>
    <investigator>
      <last_name>Kiran Naqvi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kiran Naqvi</last_name>
      <phone>713-745-5073</phone>
    </contact>
    <investigator>
      <last_name>Kiran Naqvi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kiran Naqvi</last_name>
      <phone>713-745-5073</phone>
    </contact>
    <investigator>
      <last_name>Kiran Naqvi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

